Ascendis Pharma ADR (ASND) Stock Price, Quote & News

Company Profile

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clini...

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 22 22 44

Website: ascendispharma.com

Address:

Tuborg Boulevard 12, Hellerup, Denmark

AlertsAndNews Jun. 13 at 8:52 PM

$ASND Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism "Multi-organ system and quality-of-life benefits sustained through three and a half years 86% response rate for the multi-component endpoint 89% of patients completed the three-and-a-half-year trial"

0 · Reply

notreload_ai Jun. 12 at 12:47 PM

$MBX reported one-year canvuparatide data showing 57% of patients achieved the primary endpoint in chronic hypoparathyroidism. Despite consistent results and kidney/bone benefits, shares fell on durability concerns versus expectations and $ASND Yorvipath. https://notreload.xyz/xy/mbx-biosciences-canvuparatide-misses-market-expectations/

0 · Reply

Hognose Jun. 11 at 4:37 PM

$RYTM $ASND two big buyout targets. $XBI people sleeping on them. Buy and hold.

0 · Reply

Hognose Jun. 11 at 3:06 PM

$ASND over looked bio here. De risked. Buyout candidate $XBI .

1 · Reply

Hognose Jun. 11 at 2:05 PM

$ASND back to 240.

0 · Reply

Hognose Jun. 11 at 1:58 PM

$ASND buyout candidate

0 · Reply

Hognose Jun. 10 at 1:51 PM

$ASND $PRAX too $RYTM $XBI

0 · Reply

Hognose Jun. 10 at 1:47 PM

$ASND $RYTM next big two buyout candidates $XBI watch these. Added on dips.

0 · Reply

Hognose Jun. 10 at 1:42 PM

$ASND back to 250 soon.

0 · Reply

Hognose Jun. 10 at 1:40 PM

$ASND cheap on that dip.

0 · Reply

Ascendis Pharma completes Phase 3 PaTHway Trial

Jun 13, 2026, 4:00 PM EDT - 11 days ago

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

2026-06-11T20:14:58.000Z - 13 days ago

Ascendis Pharma announces five-year data from PaTH Forward Trial

Jun 11, 2026, 4:01 PM EDT - 13 days ago

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

2026-06-09T11:42:07.000Z - 15 days ago

Ascendis Pharma ‘oversold’ following ITC development, says Oppenheimer

BMRN

Jun 8, 2026, 4:59 PM EDT - 16 days ago

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

2026-05-18T20:26:36.000Z - 5 weeks ago

Ascendis Pharma initiated with a Buy at Citi

2026-05-15T12:41:33.000Z - 5 weeks ago

Ascendis Pharma price target raised to $329 from $324 at Evercore ISI

2026-05-11T09:20:44.000Z - 6 weeks ago

Ascendis Pharma price target raised to $345 from $342 at Barclays

2026-05-08T10:34:05.000Z - 6 weeks ago

Ascendis Pharma price target lowered to $326 from $330 at Wells Fargo

2026-05-07T19:27:17.000Z - 6 weeks ago

Ascendis Pharma reports Q1 adjusted EPS EUR 0.29, consensus EUR (0.15)

May 7, 2026, 8:00 AM EDT - 6 weeks ago

Ascendis Pharma Earnings Call Transcript: Q1 2026

May 7, 2026, 8:00 AM EDT - 6 weeks ago

Ascendis Pharma Earnings release: Q1 2026

May 7, 2026, 7:30 AM EDT - 6 weeks ago

Ascendis Pharma Reports First Quarter 2026 Financial Results

May 6, 2026, 4:01 PM EDT - 7 weeks ago

New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years

Apr 30, 2026, 4:01 PM EDT - 7 weeks ago

Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026

Apr 21, 2026, 4:31 PM EDT - 2 months ago

Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028

2026-04-20T12:12:58.000Z - 2 months ago

Ascendis Pharma announces commencement of trading of shares on Nasdaq

Apr 20, 2026, 8:00 AM EDT - 2 months ago

Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq

2026-04-16T11:52:18.000Z - 2 months ago

Ascendis Pharma price target raised to $292 from $262 at BofA

2026-04-08T16:07:08.000Z - 2 months ago

Ascendis Pharma to list ordinary shares directly on Nasdaq

Apr 8, 2026, 12:00 PM EDT - 2 months ago

Ascendis Pharma to List Ordinary Shares Directly on Nasdaq

2026-04-08T12:17:11.000Z - 2 months ago

Ascendis Pharma announces new data from COACH trial

Apr 8, 2026, 8:01 AM EDT - 2 months ago

New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP's Benefits Beyond Linear Growth in Children with Achondroplasia

2026-04-06T20:05:37.000Z - 2 months ago

Ascendis Pharma gets orphan drug exclusivity for Yuviwel, launches in the U.S.

Apr 6, 2026, 4:01 PM EDT - 2 months ago

Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States

2026-03-17T12:56:23.000Z - 3 months ago

Ascendis Pharma’s TransCon shows efficacy and safety in Turner Syndrome

Mar 17, 2026, 8:30 AM EDT - 3 months ago

New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52

2026-03-16T13:27:02.000Z - 3 months ago

Ascendis Pharma assumed with a Buy at Jefferies

2026-03-16T12:17:46.000Z - 3 months ago

Ascendis Pharma announces new data from Navepegritide trial

Mar 16, 2026, 8:00 AM EDT - 3 months ago

New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026

2026-03-04T20:36:42.000Z - 4 months ago

Ascendis Pharma price target raised to $332 from $325 at Stifel

2026-03-03T14:03:45.000Z - 4 months ago

Ascendis Pharma price target raised to $275 from $250 at RBC Capital

Mar 2, 2026, 11:10 AM EST - 4 months ago

Ascendis Pharma Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 8:43 AM EST - 4 months ago

Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 8:00 AM EST - 4 months ago

Ascendis Pharma Transcript: FDA announcement

Mar 2, 2026, 8:00 AM EST - 4 months ago

Ascendis Pharma Press release: FDA announcement

Mar 2, 2026, 8:00 AM EST - 4 months ago

Ascendis Pharma Slides: FDA announcement

Feb 27, 2026, 6:04 PM EST - 4 months ago

Ascendis wins U.S. approval for therapy for children with dwarfism

Feb 27, 2026, 5:57 PM EST - 4 months ago

FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older

Feb 11, 2026, 4:30 PM EST - 4 months ago

Ascendis Pharma Earnings Call Transcript: Q4 2025

Feb 11, 2026, 4:30 PM EST - 4 months ago

Ascendis Pharma Annual report: Q4 2025

Feb 11, 2026, 4:30 PM EST - 4 months ago

Ascendis Pharma Earnings release: Q4 2025

Feb 11, 2026, 4:01 PM EST - 4 months ago

Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results

Feb 4, 2026, 4:01 PM EST - 5 months ago

Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026

Jan 12, 2026, 10:30 AM EST - 5 months ago

Ascendis Pharma Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 10:30 AM EST - 5 months ago

Ascendis Pharma Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 6:01 PM EST - 5 months ago

Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 4:30 PM EST - 5 months ago

Ascendis Pharma Transcript: Study Update

Jan 8, 2026, 4:30 PM EST - 5 months ago

Ascendis Pharma Press release: Study Update

Jan 8, 2026, 4:30 PM EST - 5 months ago

Ascendis Pharma Slides: Study Update

Jan 8, 2026, 4:01 PM EST - 5 months ago

Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)

Jan 5, 2026, 8:30 AM EST - 6 months ago

Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 10:37 AM EST - 6 months ago

Eight stock picks to play one of the healthiest corners of the market

ALNY INSM MASI NTRA PODD UNH WGS

Dec 8, 2025, 1:54 PM EST - 7 months ago

Final Trades: Ascendis Pharma, Monolithic Power, the IYC and the GPIQ

IYC MPWR GPIQ

Nov 25, 2025, 6:21 PM EST - 7 months ago

US FDA extends review of Ascendis Pharma's therapy for children with dwarfism

Nov 25, 2025, 6:15 PM EST - 7 months ago

Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia

Nov 17, 2025, 4:01 PM EST - 7 months ago

Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics

Nov 12, 2025, 4:30 PM EST - 8 months ago

Ascendis Pharma Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 8 months ago

Ascendis Pharma Earnings release: Q3 2025

Nov 12, 2025, 4:01 PM EST - 8 months ago

Ascendis Pharma Reports Third Quarter 2025 Financial Results

Nov 7, 2025, 8:30 AM EST - 8 months ago

New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism

Nov 5, 2025, 4:01 PM EST - 8 months ago

Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025

Nov 3, 2025, 4:01 PM EST - 8 months ago

3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025

Nov 3, 2025, 9:58 AM EST - 8 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

Oct 8, 2025, 4:01 PM EDT - 9 months ago

Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia

Sep 3, 2025, 8:00 AM EDT - 10 months ago

Ascendis Pharma Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 2, 2025, 4:01 PM EDT - 10 months ago

Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025

Aug 28, 2025, 4:01 PM EDT - 10 months ago

Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Ascendis Pharma Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Ascendis Pharma Earnings release: Q2 2025

Aug 7, 2025, 4:01 PM EDT - 11 months ago

Ascendis Pharma Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 4:01 PM EDT - 11 months ago

Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

Jul 28, 2025, 7:00 AM EDT - 11 months ago

FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency

Jul 14, 2025, 4:01 PM EDT - 1 year ago

New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life

Jul 7, 2025, 4:01 PM EDT - 1 year ago

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Ascendis Pharma Transcript: Study Update

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Ascendis Pharma Press release: Study Update

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Ascendis Pharma Slides: Study Update

Jun 9, 2025, 7:00 AM EDT - 1 year ago

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

Jun 2, 2025, 8:00 AM EDT - 1 year ago

FDA Accepts TransCon® CNP NDA for Priority Review

May 20, 2025, 6:00 AM EDT - 1 year ago

Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction

May 15, 2025, 8:00 AM EDT - 1 year ago

Ascendis Pharma Slides: Investor Presentation

May 13, 2025, 4:01 PM EDT - 1 year ago

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

May 12, 2025, 4:45 PM EDT - 1 year ago

New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

May 5, 2025, 8:30 AM EDT - 1 year ago

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Ascendis Pharma Earnings Call Transcript: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Ascendis Pharma Earnings release: Q1 2025

May 1, 2025, 4:01 PM EDT - 1 year ago

Ascendis Pharma Reports First Quarter 2025 Financial Results

Apr 24, 2025, 4:01 PM EDT - 1 year ago

Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025

Mar 31, 2025, 4:01 PM EDT - 1 year ago

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

Mar 4, 2025, 11:10 AM EST - 1 year ago

Ascendis Pharma Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 24, 2025, 4:01 PM EST - 1 year ago

Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 12, 2025, 4:30 PM EST - 1 year ago

Ascendis Pharma Earnings Call Transcript: Q4 2024

Feb 12, 2025, 4:30 PM EST - 1 year ago

Ascendis Pharma Annual report: Q4 2024

Feb 12, 2025, 4:30 PM EST - 1 year ago

Ascendis Pharma Earnings release: Q4 2024

Feb 12, 2025, 4:05 PM EST - 1 year ago

Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

AlertsAndNews Jun. 13 at 8:52 PM

0 · Reply

notreload_ai Jun. 12 at 12:47 PM

0 · Reply

Hognose Jun. 11 at 4:37 PM

$RYTM $ASND two big buyout targets. $XBI people sleeping on them. Buy and hold.

0 · Reply

Hognose Jun. 11 at 3:06 PM

$ASND over looked bio here. De risked. Buyout candidate $XBI .

1 · Reply

Hognose Jun. 11 at 2:05 PM

$ASND back to 240.

0 · Reply

Hognose Jun. 11 at 1:58 PM

$ASND buyout candidate

0 · Reply

Hognose Jun. 10 at 1:51 PM

$ASND $PRAX too $RYTM $XBI

0 · Reply

Hognose Jun. 10 at 1:47 PM

$ASND $RYTM next big two buyout candidates $XBI watch these. Added on dips.

0 · Reply

Hognose Jun. 10 at 1:42 PM

$ASND back to 250 soon.

0 · Reply

Hognose Jun. 10 at 1:40 PM

$ASND cheap on that dip.

0 · Reply

Hognose Jun. 10 at 1:36 PM

$RYTM $ASND $ABVX buyout candidates. NUVL was one. Just got bought. $XBI

0 · Reply

Nosh Jun. 9 at 1:18 PM

$ASND B. Jensen. Here.

0 · Reply

Hognose Jun. 9 at 10:50 AM

$RYTM $ABVX $NUVL $CAPR $ASND recently all chopped down. But companies with major drugs and potential buyouts. NUVL JUST GOT GRABBED.

1 · Reply

explover May. 29 at 3:30 PM

$BMRN $ASND, what's this, a pair trade position unwinding?

0 · Reply

Doozio May. 26 at 6:00 PM

$TSLA has yet to $ASND thru da $$$ yet $DAVE while others just start TTWO FLY away n da 🐑 are in cash again before da $SEZL is done. They r fookin $NUTX ONTO 🐒🍌🧠⏰♾️ ❤️👑🌈🦄

0 · Reply

Doozio May. 24 at 5:59 PM

$RPRX whuts gonna happen wen $XBI finally begins to $ASND ONTO 🐒🍌🧠⏰♾️

0 · Reply

techj2022 May. 22 at 2:30 AM

$ASND Weekly candle highly constructive. $XBI

0 · Reply

CapitalMonk May. 11 at 5:16 PM

$ASND Price: $238.02 (-0.27%) Trend: Bullish Market Bias (7D): Bullish Bias 📈 Expected Range: ±1.37% RSI: 48.7 | Momentum: Moderate Volume: -71.6% vs avg Volatility: 2.74% Support: $216.22 | Resistance: $250.27 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25

0 · Reply

Doozio May. 7 at 6:15 PM

$ASND Thursday 🐑

0 · Reply

Pika_Capital May. 7 at 6:03 PM

$ASND good quarter. Idiots in the morning were selling as usual

2 · Reply

Doozio May. 7 at 2:13 PM

Thursday 🐑 🎁s then da 🧠 can $EXEL and $ASND on FRYday ONTO 🐒🍌🧠⏰♾️

0 · Reply

OpenOutcrier May. 7 at 12:49 PM

$ASND (-4.7% pre) Ascendis lines up $187.5M voucher sale after YUVIWEL approval https://ooc.bz/l/101500

0 · Reply

Market Cap	14.22B
Revenue (ttm)	814.76M
Net Income (ttm)	-258.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	50.09
Profit Margin	-31.67%
Debt to Equity Ratio	1.84

Volume	476,200
Avg Vol	686,488
Day's Range	N/A - N/A
Shares Out	62.38M
Stochastic %K	89%
Beta	0.39
Analysts	Strong Sell
Price Target	$298.28